Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 72.11 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985
BIOVERATIV INC0.00%6 515
BLUEBIRD BIO INC125.45%6 499
TESARO INC-13.44%6 307
TONGHUA DONGBAO PHARMACEUTI..-0.41%5 647
NEUROCRINE BIOSCIENCES, INC..52.35%5 208
JUNO THERAPEUTICS INC130.24%4 881
HUALAN BIOLOGICAL ENGINEERI..--.--%4 032
CLOVIS ONCOLOGY INC77.22%3 788
PEPTIDREAM INC-42.85%3 676
BEIGENE LTD (ADR)176.78%3 561
More Results
Financials ($)
Sales 2017 25 966 M
EBIT 2017 15 929 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart GILEAD SCIENCES
Duration : Period : Day
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Duration : Period : Week
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders